10 steps for a successful global economic model

Jul 25, 2022

Written by Beth Hancock, Senior Consultant Health Economist

Pharmaceutical companies often develop global cost-effectiveness and budget impact models, with the aim of adapting them for specific countries. In principle, this is an efficient and streamlined process, but the challenge of developing a single model for diverse healthcare systems and health technology assessment (HTA) processes means that it’s rarely straightforward.

Those familiar with the development of global models might recognise the following pitfalls:

  • Sharing a finalised global model with participating countries, only to find that a further change is required after adaptations have already begun
  • Learning that a key comparator for a subset of countries has not been included when the global model is close to finalisation
  • Including a complex modelling component to meet the needs of a specific country that is a hindrance to other countries and is difficult to remove without breaking the model
  • A country is close to submission and wishes to know the feedback from other HTA bodies on a key model uncertainty, but a centralised repository of feedback from completed and ongoing HTA appraisals does not exist.

Successful global models, on the other hand, minimise the time, effort, and resource required across both the participating countries and the global team, and give each country a strong starting position for reimbursement success. But how can this be done?

The team at Source Health Economics has developed global economic models across cardiovascular disease, oncology, muscular dystrophy, liver disease, haemophilia, retinal conditions, and skin conditions. In the process, we have established a set of guiding principles to develop a successful global model (provided in the table below). You will note that some of these principles apply to the development of all models, but the impact of errors or mis-steps is amplified in a model distributed globally. As we continue to work with our clients on the development of these models, we expect this list to grow, adapt, and evolve as we face new challenges and identify new solutions – but for now, we hope you find this useful.

If you would like to learn more about global economic models or discuss a current challenge, please contact us at Source Health Economics, an independent consultancy specialising in evidence generation, health economics, and communication.


More Insights

Evaluating Health Inequalities: NICE’s Modular Update

Evaluating Health Inequalities: NICE’s Modular Update

Written by Paloma Charlesworth (Assistant Project Manager)   Background  Health inequalities are systematic, avoidable, and unjust differences in health outcomes between patient groups. Despite decades of policy and research, they not ... Read more

HTA monthly – October 2025

HTA monthly – October 2025

By Kiera Lander   October brought real movement across the health technology assessment (HTA) landscape — not just in HealthTech, but across medicines, strategy, and international collaboration. From National Institute for Health and ... Read more

RAISE guidance – maintaining SLR standards in an AI-assisted future

RAISE guidance – maintaining SLR standards in an AI-assisted future

Written by Gwennie Ogilby (Associate Systematic Review Analyst) and Tom Metcalf (Senior Systematic Review Analyst)   Systematic literature reviews (SLRs) are considered one of the strongest forms of evidence to guide healthcare ... Read more

Thought Piece: How do we Reconcile Commoditisation and Strategic Value in Market Access?

Thought Piece: How do we Reconcile Commoditisation and Strategic Value in Market Access?

Written by Dan Spacie, CEO of SCIRIS   Executive Summary Market access services are undergoing a dual transformation. On one hand, technological advances and procurement pressures are driving commoditisation—standardising deliverables and ... Read more